PREDICTING THE RISK OF GRAVES DISEASE RELAPSE: COMMENTARY ON "THYROID PEROXIDASE ANTIBODY POSITIVITY IS ASSOCIATED WITH RELAPSE-FREE SURVIVAL FOLLOWING ANTITHYROID DRUG TREATMENT FOR GRAVES DISEASE"

被引：0
|
作者：
Gallo, D. [1 ]
Tanda, M. L. [1 ]
Piantanida, E. [1 ,2 ]
机构：
[1] Univ Insubria, Dept Med & Surg, Endocrine Unit, Viale Borri 57, I-21100 Varese, Italy
[2] ASST Sette Laghi, Viale Borri 57, I-21100 Varese, Italy
来源：
ENDOCRINE PRACTICE | 2020年 / 26卷 / 09期
关键词：
HYPERTHYROIDISM; THERAPY;
D O I：
10.4158/EP-2020-0230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1039 / 1041
页数：3
相关论文
共 50 条
  • [21] Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management
    Masiello, E.
    Veronesi, G.
    Gallo, D.
    Premoli, P.
    Bianconi, E.
    Rosetti, S.
    Cusini, C.
    Sabatino, J.
    Ippolito, S.
    Piantanida, E.
    Tanda, M. L.
    Chiovato, L.
    Wiersinga, W. M.
    Bartalena, L.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2018, 41 (12): : 1425 - 1432
  • [22] When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
    Park, Suyeon
    Song, Eyun
    Oh, Hye-Seon
    Kim, Mijin
    Jeon, Min Ji
    Kim, Won Gu
    Kim, Tae Yong
    Shong, Young Kee
    Kim, Doo Man
    Kim, Won Bae
    ENDOCRINE, 2019, 65 (02) : 348 - 356
  • [23] When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?
    Suyeon Park
    Eyun Song
    Hye-Seon Oh
    Mijin Kim
    Min Ji Jeon
    Won Gu Kim
    Tae Yong Kim
    Young Kee Shong
    Doo Man Kim
    Won Bae Kim
    Endocrine, 2019, 65 : 348 - 356
  • [24] Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management
    E. Masiello
    G. Veronesi
    D. Gallo
    P. Premoli
    E. Bianconi
    S. Rosetti
    C. Cusini
    J. Sabatino
    S. Ippolito
    E. Piantanida
    M. L. Tanda
    L. Chiovato
    W. M. Wiersinga
    L. Bartalena
    Journal of Endocrinological Investigation, 2018, 41 : 1425 - 1432
  • [25] Thyroglobulin Autoantibodies Are Associated with Refractoriness to Antithyroid Drug Treatment for Graves' Disease
    Katahira, Masahito
    Ogata, Hidetada
    INTERNAL MEDICINE, 2016, 55 (12) : 1519 - 1524
  • [26] Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease
    Quadbeck, B
    Hoermann, R
    Roggenbuck, U
    Hahn, S
    Mann, K
    Janssen, OE
    THYROID, 2005, 15 (09) : 1047 - 1054
  • [27] The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy
    Rotondi, Mario
    Cappelli, Carlo
    Pirali, Barbara
    Pirola, Ilenia
    Magri, Flavia
    Fonte, Rodolfo
    Castellano, Maurizio
    Rosei, Enrico Agabiti
    Chiovato, Luca
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10): : 3985 - 3988
  • [28] The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves' disease
    Kus, Aleksander
    Szymanskit, Konrad
    Peeters, Robin P.
    Miskiewicz, Piotr
    Porcu, Eleonora
    Pistis, Giorgio
    Sanna, Serena
    Naitza, Silvia
    Ploski, Rafal
    Medici, Marco
    Bednarczuk, Tomasz
    CLINICAL ENDOCRINOLOGY, 2015, 83 (04) : 556 - 562
  • [29] Seasonal variation in relapse rate of Graves' disease after thionamide drug treatment
    Misaki, T
    Iida, Y
    Kasagi, K
    Konishi, J
    ENDOCRINE JOURNAL, 2003, 50 (06) : 669 - 672
  • [30] Thyroid Peroxidase Antibody is Associated with Plasma Homocysteine Levels in Patients with Graves' Disease
    Li, Fang
    Aji, Gulibositan
    Wang, Yun
    Lu, Zhiqiang
    Ling, Yan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2020, 128 (01) : 8 - 14
12345